AU Patent

AU2024234194A1 — Panras inhibitor antibody-drug conjugates and methods of use thereof

Assigned to Novartis AG · Expires 2025-08-07 · 1y expired

What this patent protects

Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise a panRAS inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conj…

USPTO Abstract

Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise a panRAS inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising panRAS inhibitor drug moiety and methods of making same are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024234194A1
Jurisdiction
AU
Classification
—
Expires
2025-08-07
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.